Andreani Marco, Gianolini Monica Emma, Testi Manuela, Battarra MariaRosa, Tiziana Galluccio, Morrone Aldo, Sodani Pietro, Lucarelli Guido, Roncarolo Maria-Grazia, Gregori Silvia
a Laboratory of Immunogenetics and Transplant Biology; IME Foundation at Polyclinic of Tor Vergata ; Rome , Italy.
b San Raffaele Telethon Institute for Gene Therapy (TIGET); Division of Regenerative Medicine; Stem Cells and Gene Therapy, IRCCS San Raffaele Scientific Institute ; Milan , Italy.
Chimerism. 2014;5(3-4):75-9. doi: 10.1080/19381956.2015.1103423. Epub 2015 Dec 9.
In a cohort of β-Thalassemia (β-Thal) transplanted with haploidentical-HSCT we identified one transplanted patient characterized by persistent mixed chimerism (PMC) for several months after HSCT. In this unique β-Thal patient we assessed the donor engraftment overtime after transplantation, the potential loss of the non-shared HLA haplotype, and the presence of CD49b(+)LAG-3(+) T regulatory type 1 (Tr1) cells, previously demonstrated to be associated with PMC after HLA-related HSCT for β-Thal. The majority of the patient's erythrocytes were of donor origin, whereas T cells were initially mostly derived from the recipient, no HLA loss, but an increased frequency of circulating Tr1 cells were observed. For the first time, we showed that when the proportion of residual donor cells decreases, the frequency of CD49b(+)LAG-3(+) Tr1 cells declines, reaching the levels present in healthy subjects. These findings confirm previous results obtained in transplant related settings for β-Thal, and supported the central role of Tr1 cells in promoting and maintaining PMC after allo-HSCT.
在一组接受单倍体相合造血干细胞移植(haploidentical-HSCT)的β地中海贫血(β-Thal)患者中,我们发现一名移植患者在HSCT后数月表现为持续混合嵌合体(PMC)。在这名独特的β-Thal患者中,我们评估了移植后随时间推移的供体植入情况、非共享HLA单倍型的潜在丢失,以及CD49b(+)LAG-3(+) 1型调节性T(Tr1)细胞的存在情况,此前已证明这些细胞与β-Thal患者接受HLA相关HSCT后的PMC有关。患者的大多数红细胞来自供体,而T细胞最初大多源自受体,未出现HLA丢失,但观察到循环Tr1细胞频率增加。我们首次表明,当残余供体细胞比例下降时,CD49b(+)LAG-3(+) Tr1细胞频率降低,达到健康受试者中的水平。这些发现证实了先前在β-Thal移植相关研究中获得的结果,并支持了Tr1细胞在异基因HSCT后促进和维持PMC中的核心作用。